BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lonardo A, Suzuki A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. J Clin Med 2020;9:E1278. [PMID: 32354182 DOI: 10.3390/jcm9051278] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 25.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim Y, Chang Y, Ryu S, Wild SH, Byrne CD. NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status. Hepatology 2022;76:1755-65. [PMID: 35514152 DOI: 10.1002/hep.32560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Izquierdo AG, Carreira MC, Rodriguez-carnero G, Perez-lois R, Seoane LM, Casanueva FF, Crujeiras AB. Gender Dimorphism in Hepatic Carcinogenesis-Related Gene Expression Associated with Obesity as a Low-Grade Chronic Inflammatory Disease. IJMS 2022;23:15002. [DOI: 10.3390/ijms232315002] [Reference Citation Analysis]
3 Perez-diaz-del-campo N, Castelnuovo G, Caviglia GP, Armandi A, Rosso C, Bugianesi E. Role of Circadian Clock on the Pathogenesis and Lifestyle Management in Non-Alcoholic Fatty Liver Disease. Nutrients 2022;14:5053. [DOI: 10.3390/nu14235053] [Reference Citation Analysis]
4 Vachher M, Bansal S, Kumar B, Yadav S, Burman A. Deciphering the role of aberrant DNA methylation in NAFLD and NASH. Heliyon 2022;8:e11119. [PMID: 36299516 DOI: 10.1016/j.heliyon.2022.e11119] [Reference Citation Analysis]
5 Savva C, Helguero LA, González-Granillo M, Melo T, Couto D, Angelin B, Domingues MR, Li X, Kutter C, Korach-André M. Molecular programming modulates hepatic lipid metabolism and adult metabolic risk in the offspring of obese mothers in a sex-specific manner. Commun Biol 2022;5:1057. [PMID: 36195702 DOI: 10.1038/s42003-022-04022-3] [Reference Citation Analysis]
6 Man S, Lv J, Yu C, Deng Y, Yin J, Wang B, Li L, Liu H. Association between metabolically healthy obesity and non-alcoholic fatty liver disease. Hepatol Int. [DOI: 10.1007/s12072-022-10395-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Russo G, Manicardi V, Rossi M, Orsi E, Solini A. Sex- and gender-differences in chronic long-term complications of type 1 and type 2 diabetes mellitus in Italy. Nutrition, Metabolism and Cardiovascular Diseases 2022. [DOI: 10.1016/j.numecd.2022.08.011] [Reference Citation Analysis]
8 Zhang X, Mou Y, Aribas E, Amiri M, Nano J, Bramer WM, Kavousi M, de Knegt RJ, Asllanaj E, Ghanbari M. Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis. Genes 2022;13:966. [DOI: 10.3390/genes13060966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
10 Alalwani J, Eljazzar S, Basil M, Tayyem R. The impact of health status, diet and lifestyle on non‐alcoholic fatty liver disease: Narrative review. Clinical Obesity. [DOI: 10.1111/cob.12525] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Uchida T, Fujiwara K, Nishioji K, Kobayashi M, Kano M, Seko Y, Yamaguchi K, Itoh Y, Kadotani H. Medical checkup data analysis method based on LiNGAM and its application to nonalcoholic fatty liver disease. Artificial Intelligence in Medicine 2022. [DOI: 10.1016/j.artmed.2022.102310] [Reference Citation Analysis]
12 Von-hafe M, Borges-canha M, Vale C, Leite AR, Sérgio Neves J, Carvalho D, Leite-moreira A. Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review. Metabolites 2022;12:298. [DOI: 10.3390/metabo12040298] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
13 Ghandian S, Thapa R, Garikipati A, Barnes G, Green‐saxena A, Calvert J, Mao Q, Das R. Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis. JGH Open. [DOI: 10.1002/jgh3.12716] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Jouffe C, Weger BD, Martin E, Atger F, Weger M, Gobet C, Ramnath D, Charpagne A, Morin-Rivron D, Powell EE, Sweet MJ, Masoodi M, Uhlenhaut NH, Gachon F. Disruption of the circadian clock component BMAL1 elicits an endocrine adaption impacting on insulin sensitivity and liver disease. Proc Natl Acad Sci U S A 2022;119:e2200083119. [PMID: 35238641 DOI: 10.1073/pnas.2200083119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Choi JM, Park HE, Han YM, Lee J, Lee H, Chung SJ, Lim SH, Yim JY, Chung GE. Non-alcoholic/Metabolic-Associated Fatty Liver Disease and Helicobacter pylori Additively Increase the Risk of Arterial Stiffness. Front Med 2022;9:844954. [DOI: 10.3389/fmed.2022.844954] [Reference Citation Analysis]
16 Kim W. Hepatocellular Carcinoma. Sex/Gender-Specific Medicine in the Gastrointestinal Diseases 2022. [DOI: 10.1007/978-981-19-0120-1_15] [Reference Citation Analysis]
17 Pelechá M, Villanueva-bádenas E, Timor-lópez E, Donato MT, Tolosa L. Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 2022;11:86. [DOI: 10.3390/antiox11010086] [Reference Citation Analysis]
18 Cho EJ, Jung GC, Kwak MS, Yang JI, Yim JY, Yu SJ, Chung GE. Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population. Diagnostics (Basel) 2021;11:2233. [PMID: 34943469 DOI: 10.3390/diagnostics11122233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
19 Jeong SM, Lee HR, Jang W, Kim D, Yoo JE, Jeon KH, Jin SM, Han K, Shin DW. Sex differences in the association between nonalcoholic fatty liver disease and Parkinson's disease. Parkinsonism Relat Disord 2021;93:19-26. [PMID: 34763304 DOI: 10.1016/j.parkreldis.2021.10.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J, Chen W, Hylemon PB, Zhou H. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. Cells 2021;10:2806. [PMID: 34831031 DOI: 10.3390/cells10112806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
21 Musto J, Spengler EK, German MN. Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2021;20:97-107. [DOI: 10.1007/s11901-021-00568-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Nakanishi N, Hashimoto Y, Okamura T, Ohbora A, Kojima T, Hamaguchi M, Fukui M. A weight regain of 1.5 kg or more and lack of exercise are associated with nonalcoholic fatty liver disease recurrence in men. Sci Rep 2021;11:19992. [PMID: 34620897 DOI: 10.1038/s41598-021-99036-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Seo JY, Bae JH, Kwak MS, Yang JI, Chung SJ, Yim JY, Lim SH, Chung GE. The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease. Biomedicines 2021;9:1401. [PMID: 34680518 DOI: 10.3390/biomedicines9101401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
24 Della Torre S. Beyond the X Factor: Relevance of Sex Hormones in NAFLD Pathophysiology. Cells 2021;10:2502. [PMID: 34572151 DOI: 10.3390/cells10092502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
25 Kovačević S, Elaković I, Vojnović Milutinović D, Nikolić-Kokić A, Blagojević D, Matić G, Tappy L, Djordjevic A, Brkljačić J. Fructose-Rich Diet Attenuates Stress-Induced Metabolic Disturbances in the Liver of Adult Female Rats. J Nutr 2021:nxab294. [PMID: 34510217 DOI: 10.1093/jn/nxab294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Robeva R, Mladenović D, Vesković M, Hrnčić D, Bjekić-Macut J, Stanojlović O, Livadas S, Yildiz BO, Macut D. The interplay between metabolic dysregulations and non-alcoholic fatty liver disease in women after menopause. Maturitas 2021;151:22-30. [PMID: 34446275 DOI: 10.1016/j.maturitas.2021.06.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
27 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
28 Savva C, Helguero LA, González-granillo M, Melo T, Couto D, Angelin B, Rosário Domingues M, Li X, Kutter C, Korach-andré M. Molecular programming in utero modulates hepatic lipid metabolism and adult metabolic risk in obese mother offspring in a sex-specific manner.. [DOI: 10.1101/2021.05.26.445738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sun WL, Yang JW, Dou HY, Li GQ, Li XY, Shen L, Ji HF. Anti-inflammatory effect of luteolin is related to the changes in the gut microbiota and contributes to preventing the progression from simple steatosis to nonalcoholic steatohepatitis. Bioorg Chem 2021;112:104966. [PMID: 33991837 DOI: 10.1016/j.bioorg.2021.104966] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
30 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 25.0] [Reference Citation Analysis]
31 Lamos EM, Kristan M, Siamashvili M, Davis SN. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Rev Clin Pharmacol 2021;14:837-52. [PMID: 33882758 DOI: 10.1080/17512433.2021.1917374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Lee YS, Hwang LC, Hsu HY, Tsou MT. The Association Between Different Obesity Phenotypes and Liver Fibrosis Scores in Elderly Individuals with Fatty Liver in Taiwan. Diabetes Metab Syndr Obes 2021;14:1473-83. [PMID: 33833538 DOI: 10.2147/DMSO.S302207] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
34 Alswat K, Sanai FM, Al-Hamoudi W, Ismail M, Dahlan Y, AlGhamdi HS, Altraif I, Alalwan A, Babatin MMA, Alqahtani SA. Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. Diabetes Metab Syndr Obes 2021;14:1167-75. [PMID: 33762835 DOI: 10.2147/DMSO.S300051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Rim JH, Youk T, Gee HY, Cho J, Yoo J. Dynamic Chronological Changes in Serum Triglycerides Are Associated With the Time Point for Non-alcoholic Fatty Liver Disease Development in the Nationwide Korean Population Cohort. Front Med (Lausanne) 2021;8:637241. [PMID: 33777980 DOI: 10.3389/fmed.2021.637241] [Reference Citation Analysis]
36 Dongiovanni P, Paolini E, Corsini A, Sirtori CR, Ruscica M. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Eur J Clin Invest 2021;51:e13519. [PMID: 33583033 DOI: 10.1111/eci.13519] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
37 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
38 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites 2021;11:73. [DOI: 10.3390/metabo11020073] [Reference Citation Analysis]
39 Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites 2021;11:73. [PMID: 33513761 DOI: 10.3390/metabo11020073] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 65.0] [Reference Citation Analysis]
40 Lin IT, Lee MY, Wang CW, Wu DW, Chen SC. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population. Int J Environ Res Public Health 2021;18:857. [PMID: 33498329 DOI: 10.3390/ijerph18030857] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
41 Wegermann K, Garrett ME, Zheng J, Coviello A, Moylan CA, Abdelmalek MF, Chow SC, Guy CD, Diehl AM, Ashley-Koch A, Suzuki A. Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD. Hepatol Commun 2021;5:598-607. [PMID: 33860118 DOI: 10.1002/hep4.1668] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
42 Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci 2020;21:E9646. [PMID: 33348908 DOI: 10.3390/ijms21249646] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
43 Doulberis M, Papaefthymiou A, Srivastava DS, Exadaktylos AK, Katsinelos P, Kountouras J, Polyzos SA. Update on the association between non-alcoholic fatty liver disease and Helicobacter pylori infection. Int J Clin Pract 2021;75:e13737. [PMID: 32991019 DOI: 10.1111/ijcp.13737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Gao F, Zheng KI, Zhu PW, Li YY, Ma HL, Li G, Tang LJ, Rios RS, Liu WY, Pan XY, Targher G, Byrne CD, Chen YP, Zheng MH. FNDC5 polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. Br J Nutr 2021;126:813-24. [PMID: 33198849 DOI: 10.1017/S0007114520004559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
45 Binetti J, Bertran L, Riesco D, Aguilar C, Martínez S, Sabench F, Porras JA, Camaron J, Castillo DD, Richart C, Auguet T. Deregulated Serotonin Pathway in Women with Morbid Obesity and NAFLD. Life (Basel) 2020;10:E245. [PMID: 33081272 DOI: 10.3390/life10100245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, Carvalho D, Leite-Moreira A. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413. [PMID: 33010191 DOI: 10.1002/dmrr.3413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
47 Małecki P, Tracz J, Łuczak M, Figlerowicz M, Mazur-Melewska K, Służewski W, Mania A. Serum proteome assessment in nonalcoholic fatty liver disease in children: a preliminary study. Expert Rev Proteomics 2020;17:623-32. [PMID: 32921203 DOI: 10.1080/14789450.2020.1810020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Sookoian S, Pirola CJ. Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology. Clin Mol Hepatol. 2020;26:461-475. [PMID: 32906228 DOI: 10.3350/cmh.2020.0136] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
49 Palomar-Lever A, Barraza G, Galicia-Alba J, Echeverri-Bolaños M, Escarria-Panesso R, Padua-Barrios J, Halabe-Cherem J, Hernandez-Molina G, Chargoy-Loustaunau TN, Kimura-Hayama E. Hepatic steatosis as an independent risk factor for severe disease in patients with COVID-19: A computed tomography study. JGH Open 2020. [PMID: 32838045 DOI: 10.1002/jgh3.12395] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
50 Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
51 Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Reference Citation Analysis]